0001209191-13-053649.txt : 20131121
0001209191-13-053649.hdr.sgml : 20131121
20131121200230
ACCESSION NUMBER: 0001209191-13-053649
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131119
FILED AS OF DATE: 20131121
DATE AS OF CHANGE: 20131121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Repella Robert
CENTRAL INDEX KEY: 0001532513
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 131236588
MAIL ADDRESS:
STREET 1: 1410 PARSONS LANE
CITY: AMBLER
STATE: PA
ZIP: 19002
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2013-11-19
0
0001347178
Vanda Pharmaceuticals Inc.
VNDA
0001532513
Repella Robert
2200 PENNSYLVANIA AVENUE
SUITE 300E
WASHINGTON
DC
20037
0
1
0
0
SVP & Chief Commercial Officer
Common Stock
2013-11-19
4
S
0
2885
12.0724
D
21490
D
Common Stock
2013-11-20
4
M
0
40515
5.90
A
62005
D
Common Stock
2013-11-20
4
S
0
40515
11.8884
D
21490
D
Common Stock
2013-11-21
4
M
0
23040
5.90
A
44530
D
Common Stock
2013-11-21
4
M
0
34570
3.12
A
79100
D
Common Stock
2013-11-21
4
S
0
64100
12.1184
D
15000
D
Employee Stock Option (Right to Buy)
5.90
2013-11-20
4
M
0
40515
0.00
D
2021-10-24
Common Stock
40515
189485
D
Employee Stock Option (Right to Buy)
5.90
2013-11-21
4
M
0
23040
0.00
D
2021-10-24
Common Stock
23040
166445
D
Employee Stock Option (Right to Buy)
3.12
2013-11-21
4
M
0
34570
0.00
D
2022-12-06
Common Stock
34570
21680
D
Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of certain Restricted Stock Units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.115, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.46, inclusive.
The option becomes exercisable with respect to 25% of the shares after 12 months of continuous service with the Issuer, with the balance becoming exercisable in equal monthly installments over the next 36 months of continuous service thereafter.
50% of the shares subject to this option shall vest in 48 equal monthly installments beginning January 7, 2013 (the "Initial Vesting Date"), provided Reporting Person remains continuously employed by the Issuer through the Initial Vesting Date. 50% of the shares subject to this option shall vest upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder (the "Vesting Event"), provided Reporting Person remains continuously employed by the Issuer through the Vesting Event.
/s/ Robert Repella
2013-11-21